Sibiman bio-autonomous human-derived supermyoblast injection obtains implicit permission for clinical trials
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
knee osteoarthritis is a common chronic joint disease, also known as degenerative arthritis, characterized by the primary or secondary degenerative change of joint cartilage and bone hyperplasiacommon in the elderly, mainly affecting knee cartilage, bone and sliding membrane tissueDuring the onset of the disease, patients will have joint pain, swelling, deformationKnee deformities can occur in severe casesrecently, it was reported that Sibiman Bio's "self-contained inter-human fat proteocyte progenitor cell injection" used to treat knee osteoarthritis has been granted an implicit license by the clinicaltrial(http://Previously, Sibiman applied for an allo-in-human-derived supermyocyte injection AlloJoin to treat knee osteoarthritis has been implicitly approved by the National Drug Administration's Drug Review Center for clinical trials
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
